Contemporary use of
guideline‐based
higher potency
P2Y12
receptor inhibitor therapy in patients with
moderate‐to‐high
risk
non‐ST‐segment
elevation myocardial infarction: Results from the Canadian
ACS
reflective
II cross‐sectional
study
Clinical Cardiology(2021)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要